Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review

Table 3 Summary of included articles with most important study characteristics

Author	Ref.	Year	Score1	Number of patients	Number of IBD (CD/UC/IBDu)	Dose (med)	Follow-up (M)	Effective n (%)	Non-effective n (%)	Discontinuation	6-TGN (med)
										n (%)
Dubinsky	17	2001	Very low	10	10/0/0	40	4	7 (70)	1 (10)	2 (20)	15482
Cheung	18	2003	Very low	15	13/1/1	40	3	12 (79)	1 (7)	2 (14)	N/A
Herrlinger	19	2003	Low	37	37/0/0	40	6	21 (57)	7 (19)	9 (24)	N/A
Bonaz	21	2003	Very low	49	49/0/0	20	12	38 (78)3	6 (12)	5 (10)	6484
Dubinsky	22	2003	Very low	21	14/7/0	20	9	14 (67)	3 (14)	4 (19)	13651
Teml	23	2005	Low	20	0/14/6	20	6	11 (55)	3 (15)	6 (30)	8164
Qasim	24	2007	Very low	40	28/10/2	40	6	19 (48)	8 (20)	13 (32)	N/A
Ansari	12	2008	Low	30	30/0/0	40	6	18 (60)	5 (17)	7 (23)	8074
Almer	25	2009	Low	23	23/0/0	40	9	5 (22)	5 (22)	13 (56)	11552
Asseldonk	16	2011	Low	46	0/46/0	20	22	37 (80)3	3 (7)	6 (13)	2784
Pavlidis	15	2014	Moderate	62	21/41/0	20	6	46 (78)	11 (14)	5 (8)	8114

¹Grading based on GRADE guidelines[50,51].

²Median value in subgroup with clinical response to 6-thioguanine treatment;

³Expected value;

⁴Median value in total group, regardless of clinical response to treatment. IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; IBDu: IBD unclassified; 6-TGN: 6-thioguanine nucleotides; N/A: Not applicable; Ref: Number in reference list; Dose: Median dosage of thioguanine therapy at initiation.